MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Feb 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
MANGOCEUTICALS filed an 8-K detailing a new material agreement and equity sales.
AI Summary
On February 14, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on February 19, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks and require further investigation into the specifics.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- February 14, 2025 (date) — Date of Earliest Event Reported
- February 19, 2025 (date) — Date of Report
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
FAQ
What is the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on February 14, 2025?
The filing states that MANGOCEUTICALS, INC. entered into a material definitive agreement on February 14, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold in the unregistered sales reported?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What are the key financial statements and exhibits being filed with this 8-K?
The filing indicates that financial statements and exhibits are being included, but the specific content of these documents is not described in the excerpt.
What is the primary business of MANGOCEUTICALS, INC. based on its SIC code?
MANGOCEUTICALS, INC. is classified under SIC code 8090, which corresponds to SERVICES-MISC HEALTH & ALLIED SERVICES, NEC.
Where are MANGOCEUTICALS, INC.'s principal executive offices located?
The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding MANGOCEUTICALS, INC. (MGRX).